Last updated July 4, 2026
Key finding
HbA1c decreased from 8.36 % to 6.81 % in the test group.
This Phase 3 trial evaluated a novel semaglutide injection in Indian adults with Type 2 diabetes, showing significant reductions in HbA1c and body weight.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This Phase 3 trial evaluated a novel semaglutide injection in Indian adults with Type 2 diabetes, showing significant reductions in HbA1c and body weight.
These findings are significant as they suggest that the novel semaglutide injection could be an effective treatment option for managing Type 2 diabetes in Indian adults. By improving blood sugar control and reducing body weight, this treatment may help lower the risk of diabetes-related complications, enhancing the quality of life for patients.
The study's generalizability may be limited to the Indian population. Potential biases in self-reported outcomes were not addressed. The long-term effects of the treatment were not evaluated.
Published in
Publication details and source links for this paper.
Prabhat KS, V. V, Animesh C, et al. A Phase 3 Trial of a Novel Semaglutide Injection in Indian Adults with Type 2 Diabetes. Metabolism Open. 2026;30:100476. doi:10.1016/j.metop.2026.100476
HbA1c decreased by 1.55% in the test group (p=0.001).
Fasting plasma glucose decreased by 37.5 mg/dL in the test group.
Body weight decreased by 4.59 kg in the test group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Semaglutide and Adverse events incidence, BMI, Body weight, and 6 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
5
Related topics
9
Evidence pairs
1230
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Semaglutide → Adverse events incidence
Semaglutide → Adverse events incidence
Semaglutide → Diastolic blood pressure
Semaglutide → Diastolic blood pressure
Semaglutide → Fasting Plasma Glucose (FPG)
Semaglutide → Fasting Plasma Glucose (FPG)
Semaglutide → Postprandial hypoglycemia incidence
Semaglutide → Postprandial hypoglycemia incidence
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
11 results
9 results
11 results
11 results
9 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 32 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 12 supporting studies with generally consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
BMI
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
